文献速递肺外科

早期大细胞神经内分泌癌辅助治疗作用的界定

Defining the role of adjuvant therapy for early-stage large cell neuroendocrine carcinoma.
PubMed 文献 · J Thorac Cardiovasc Surg · 2019-09-30

辅助化疗与更长的生存期显著相关,尤其在肿瘤大于3cm的患者中,对2至3cm肿瘤可能有益,而辅助胸部放疗未与生存延长相关。

要点

  • 早期淋巴结阴性大细胞神经内分泌癌中,辅助化疗与总生存期显著延长相关。
  • 辅助化疗的生存获益在肿瘤大于3cm患者中明确,2至3cm者可能获益但倾向评分匹配后不显著。
  • 辅助胸部放疗未显示与生存延长相关,亚肺叶切除较肺叶切除生存更差。

核心结论

  • 在早期淋巴结阴性大细胞神经内分泌癌中,辅助化疗与显著更长的生存期相关,尤其对于肿瘤大于3cm者,对2至3cm肿瘤可能有益。
  • 辅助胸部放疗未与生存延长相关。

主要发现

  • 463例(26.2%)接受辅助化疗,接受者更年轻、合并症更少、更常见T2肿瘤。
  • 辅助化疗组总体5年总生存率为59.2%,未接受组为45.3%,风险比0.69(95%CI 0.58-0.82,P<.0001)。
  • T2肿瘤中辅助化疗组5年总生存率为59.8%,未接受组为42.1%,风险比0.63(95%CI 0.50-0.81,P<.0001)。
  • 肿瘤2至3cm中辅助化疗组总生存率为60.0%,未接受组为42.6%,风险比0.64(95%CI 0.46-0.8,P=.002),但倾向评分匹配后该关联不显著。
  • 肿瘤小于2cm者辅助化疗未显示生存获益;亚肺叶切除对比肺叶切除的风险比为1.40(95%CI 1.20-1.64,P<.0001)。

关键数值与推荐

  • 辅助化疗与总体、T2肿瘤及2至3cm肿瘤的生存获益相关,风险比分别为0.69、0.63和0.64。
  • 辅助胸部放疗未与生存延长相关。
  • 亚肺叶切除与更差的总生存相关,风险比1.40。

临床怎么用

  • 对于早期淋巴结阴性大细胞神经内分泌癌,尤其肿瘤大于3cm者,可考虑辅助化疗以改善生存。
  • 肿瘤2至3cm者可个体化考虑辅助化疗,但需注意倾向评分匹配后获益不显著。
  • 不推荐常规使用辅助胸部放疗;手术方式应优先选择肺叶切除而非亚肺叶切除。

局限性

  • 回顾性数据库研究可能存在选择偏倚和未测量混杂因素。
  • 倾向评分匹配后2至3cm肿瘤的生存关联不再显著,提示该亚组获益不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Large cell neuroendocrine carcinoma is a rare, high-grade neuroendocrine tumor. The mainstay of treatment for early, node-negative disease is surgical resection, and optimal adjuvant treatment strategies are not well defined. METHODS: Patients with early, node-negative large cell neuroendocrine carcinoma were identified in the National Cancer Database from 2004 to 2014. Patient, tumor, treatment, and hospital characteristics were examined. Survival differences in patients receiving adjuvant chemotherapy (AC) were evaluated using Kaplan-Meier curves, and adjusted multivariate Cox models were constructed. A conditional landmark analysis was used to address immortal time bias. T-stage-specific propensity score matching was used to address covariate imbalances between groups. RESULTS: One thousand seven hundred seventy patients were identified, of whom 463 (26.2%) received AC. Patients receiving AC were younger, less comorbid, and more likely to have T2 tumors. AC was associated with significantly longer survival, which persisted after adjustment in Cox models, for patients overall (5-year overall survival, 59.2% vs 45.3%; hazard ratio, 0.69; 95% confidence interval, 0.58-0.82; P < .0001), T2 tumors (overall survival, 59.8% vs 42.1%; hazard ratio, 0.63; 95% confidence interval, 0.50-0.81; P < .0001), and tumors 2 to 3 cm (overall survival, 60.0% vs 42.6%; hazard ratio, 0.64; 95% confidence interval, 0.46-0.8; P = .002), but not tumors smaller than 2 cm. Adjuvant chest radiotherapy was not associated with longer survival. Sublobar resection was associated with worse overall survival compared with lobectomy (hazard ratio, 1.40; 95% confidence interval, 1.20-1.64; P < .0001). Propensity score matching confirmed these findings, but the association with survival for tumors 2 to 3 cm in size was not significant. CONCLUSIONS: In this national study of early-stage large cell neuroendocrine carcinoma, AC was associated with significantly longer survival for tumors larger than 3 cm, and possibly for tumors 2 to 3 cm. Adjuvant radiation was not associated with prolonged survival.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Wakeam E, Adibfar A, Stokes S, et al. Defining the role of adjuvant therapy for early-stage large cell neuroendocrine carcinoma. J Thorac Cardiovasc Surg. 2019. PMID: 31759623. doi:10.1016/j.jtcvs.2019.09.077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。